200 related articles for article (PubMed ID: 29989208)
1. Targeting Wnt signaling pseudokinases in hematological cancers.
Karvonen H; Perttilä R; Niininen W; Barker H; Ungureanu D
Eur J Haematol; 2018 Oct; 101(4):457-465. PubMed ID: 29989208
[TBL] [Abstract][Full Text] [Related]
2. Targeting ROR1 identifies new treatment strategies in hematological cancers.
Karvonen H; Niininen W; Murumägi A; Ungureanu D
Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
[TBL] [Abstract][Full Text] [Related]
3. Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.
Sheetz JB; Mathea S; Karvonen H; Malhotra K; Chatterjee D; Niininen W; Perttilä R; Preuss F; Suresh K; Stayrook SE; Tsutsui Y; Radhakrishnan R; Ungureanu D; Knapp S; Lemmon MA
Mol Cell; 2020 Aug; 79(3):390-405.e7. PubMed ID: 32619402
[TBL] [Abstract][Full Text] [Related]
4. Wnt5a and ROR1 activate non-canonical Wnt signaling via RhoA in TCF3-PBX1 acute lymphoblastic leukemia and highlight new treatment strategies via Bcl-2 co-targeting.
Karvonen H; Perttilä R; Niininen W; Hautanen V; Barker H; Murumägi A; Heckman CA; Ungureanu D
Oncogene; 2019 Apr; 38(17):3288-3300. PubMed ID: 30631148
[TBL] [Abstract][Full Text] [Related]
5. New insights into the molecular mechanisms of ROR1, ROR2, and PTK7 signaling from the proteomics and pharmacological modulation of ROR1 interactome.
Raivola J; Dini A; Salokas K; Karvonen H; Niininen W; Piki E; Varjosalo M; Ungureanu D
Cell Mol Life Sci; 2022 May; 79(5):276. PubMed ID: 35504983
[TBL] [Abstract][Full Text] [Related]
6. The biochemistry, signalling and disease relevance of RYK and other WNT-binding receptor tyrosine kinases.
Roy JP; Halford MM; Stacker SA
Growth Factors; 2018 Apr; 36(1-2):15-40. PubMed ID: 29806777
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.
Wu H; Medeiros LJ; Young KH
Blood Rev; 2018 Jan; 32(1):8-28. PubMed ID: 28802908
[TBL] [Abstract][Full Text] [Related]
8. Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.
Zhu N; Xiao H; Wang LM; Fu S; Zhao C; Huang H
Future Oncol; 2015; 11(4):659-73. PubMed ID: 25686120
[TBL] [Abstract][Full Text] [Related]
9. A PTK7/Ror2 Co-Receptor Complex Affects Xenopus Neural Crest Migration.
Podleschny M; Grund A; Berger H; Rollwitz E; Borchers A
PLoS One; 2015; 10(12):e0145169. PubMed ID: 26680417
[TBL] [Abstract][Full Text] [Related]
10. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
11. PTK7 localization and protein stability is affected by canonical Wnt ligands.
Berger H; Breuer M; Peradziryi H; Podleschny M; Jacob R; Borchers A
J Cell Sci; 2017 Jun; 130(11):1890-1903. PubMed ID: 28420671
[TBL] [Abstract][Full Text] [Related]
12. A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib.
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vågberg J; Byström S; Olsson E; Olin T; Österborg A; Mellstedt H
PLoS One; 2018; 13(6):e0198038. PubMed ID: 29856777
[TBL] [Abstract][Full Text] [Related]
13. Functional Crosstalk Between WNT Signaling and Tyrosine Kinase Signaling in Cancer.
Anastas JN
Semin Oncol; 2015 Dec; 42(6):820-31. PubMed ID: 26615128
[TBL] [Abstract][Full Text] [Related]
14. Comparative integromics on non-canonical WNT or planar cell polarity signaling molecules: transcriptional mechanism of PTK7 in colorectal cancer and that of SEMA6A in undifferentiated ES cells.
Katoh M; Katoh M
Int J Mol Med; 2007 Sep; 20(3):405-9. PubMed ID: 17671748
[TBL] [Abstract][Full Text] [Related]
15. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy.
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Semin Cancer Biol; 2014 Dec; 29():21-31. PubMed ID: 25068995
[TBL] [Abstract][Full Text] [Related]
16. Ectopic repression of receptor tyrosine kinase-like orphan receptor 2 inhibits malignant transformation of ovarian cancer cells by reversing epithelial-mesenchymal transition.
Xu Y; Ma YH; Pang YX; Zhao Z; Lu JJ; Mao HL; Liu PS
Tumour Biol; 2017 May; 39(5):1010428317701627. PubMed ID: 28475014
[TBL] [Abstract][Full Text] [Related]
17. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
Hill RJ; Lou Y; Tan SL
Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
[TBL] [Abstract][Full Text] [Related]
18. ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
Henry CE; Llamosas E; Daniels B; Coopes A; Tang K; Ford CE
Gynecol Oncol; 2018 Mar; 148(3):576-584. PubMed ID: 29395309
[TBL] [Abstract][Full Text] [Related]
19. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
20. EPHA3 as a novel therapeutic target in the hematological malignancies.
Keane N; Freeman C; Swords R; Giles FJ
Expert Rev Hematol; 2012 Jun; 5(3):325-40. PubMed ID: 22780212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
